news paper icon

Analyzed News

UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year. [Source]

Publication Date:


Category: companyNews

Topics: rival, priced, treatment, cancer, Vitrakvi, month, lower, 2-Roche, UPDATE, Roche, Holding, from Bayer, Lilly, was approved, price, monthly, its personalized, Rozlytrek, per month, nearly


Related Articles